Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants.

Trial Profile

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2013

At a glance

  • Drugs HIV clade B DNA vaccine Inovio (Primary) ; Tavokinogene telsaplasmid
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jul 2013 Results of this trial and one other phase I trial (HVTN070) published in the Journal of Infectious Diseases according to an Inovio media release.
    • 14 Sep 2011 Results have been presented at the AIDS Vaccine Conference, and detailed in an Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top